[Federal Register Volume 72, Number 78 (Tuesday, April 24, 2007)]
[Notices]
[Pages 20344-20345]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-7717]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Summaries of Medical and Clinical Pharmacology Reviews of 
Pediatric Studies; Availability

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing the 
availability of summaries of medical and clinical pharmacology reviews 
of pediatric studies submitted in supplements for CELEBREX (celecoxib), 
COLAZAL (balsalazide), ELOXATIN (oxaliplatin), EMTRIVA (emtricitabine), 
SUPRANE (desflurane), and TOPROL-XL (metoprolol). These summaries are 
being made available consistent with the Best Pharmaceuticals for 
Children Act (the BPCA). For all pediatric supplements submitted under 
the BPCA, the BPCA requires FDA to make available to the public a 
summary of the medical and clinical pharmacology reviews of the 
pediatric studies conducted for the supplement.

ADDRESSES:  Submit written requests for single copies of the summaries 
to the Division of Drug Information (HFD-240), Center for Drug 
Evaluation and Research, Food and Drug Administration, 5600 Fishers 
Lane, Rockville, MD 20857. Please specify by product name which summary 
or summaries you are requesting. Send one self-addressed adhesive label 
to assist that office in processing your requests. See the 
SUPPLEMENTARY INFORMATION section for electronic access to the 
summaries.

FOR FURTHER INFORMATION CONTACT:  Grace Carmouze, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 22, rm. 6460, Silver Spring, MD 20993-0002, 301-
796-0700, e-mail: [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of summaries of medical and 
clinical pharmacology reviews of pediatric studies conducted for 
CELEBREX (celecoxib), COLAZAL (balsalazide), ELOXATIN (oxaliplatin), 
EMTRIVA (emtricitabine), SUPRANE (desflurane), and TOPROL-XL 
(metoprolol). The summaries are being made available consistent with 
section 9 of the BPCA (Public Law 107-109). Enacted on January 4, 2002, 
the BPCA reauthorizes, with certain important changes, the pediatric 
exclusivity program described in section 505A of the Federal Food, 
Drug, and Cosmetic Act (the act) (21 U.S.C. 355a). Section 505A of the 
act permits certain applications to obtain 6 months of marketing 
exclusivity if, in accordance with the requirements of the statute, the 
sponsor submits requested information relating to the use of the drug 
in the pediatric population.
    One of the provisions the BPCA added to the pediatric exclusivity 
program pertains to the dissemination of pediatric information. 
Specifically, for all pediatric supplements submitted under the BPCA, 
the BPCA requires FDA to make available to the public a summary of the 
medical and clinical pharmacology reviews of pediatric studies 
conducted for the supplement (21 U.S.C. 355a(m)(1)). The summaries are 
to be made available not later than 180 days after the report on the 
pediatric study is submitted to FDA (21 U.S.C. 355a(m)(1)). Consistent 
with this provision of the BPCA, FDA has posted on the Internet 
summaries of medical and clinical pharmacology reviews of pediatric 
studies submitted in supplements for CELEBREX (celecoxib), COLAZAL 
(balsalazide), ELOXATIN (oxaliplatin), EMTRIVA (emtricitabine), SUPRANE 
(desflurane), and TOPROL-XL (metoprolol). See the SUPPLEMENTARY 
INFORMATION section for electronic access to the summaries. Copies are 
also available by mail (see ADDRESSES).

[[Page 20345]]

II. Electronic Access

    Persons with access to the Internet may obtain the summaries at 
http://www.fda.gov/cder/pediatric/index.htm.

    Dated: April 16, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-7717 Filed 4-23-07; 8:45 am]
BILLING CODE 4160-01-S